Top

Breast Cancer Research and Treatment

Published in:

01-09-2017 | Epidemiology

Incidence and treatments of DCIS in octogenarians: grade matters

Authors: Erin P. Ward, Anna Weiss, Sarah L. Blair

Published in: Breast Cancer Research and Treatment | Issue 2/2017

Abstract

Purpose

The purpose of this study is to better characterize the current incidence and treatment patterns of DCIS in women greater than 80 years of age (>80) and to evaluate the effect of grade on treatment efficacy.

Methods

Retrospective observational study of women diagnosed with single primary DCIS from 2000 to 2012 in SEER. Statistics including incidence, multivariable Cox proportional hazards model and subset analysis were performed.

Results

42,899 female patients with DCIS were identified, 2566 (5.98%) were >80. Incidence of DCIS in the less than 80 (<80) cohort was 8 per 100,000 and 11.7 per 100,000 for >80. >80 patients have a similar incidence of high grade DCIS (9.8%) as compared to <80 cohort (10.7%, P = 0.246). Compared to the <80 population the >80 population received significantly less surgery (97 vs. 92%, P < 0.001) and radiation (22 vs. 47%, P < 0.001). Although on multivariate analysis surgery did not provide a survival benefit for >80 population, it conveyed a survival benefit for high grade DCIS (HR 0.14, 95% CI 02–0.68) that was not observed for low grade DCIS (HR 0.46, 95% CI 0.1–2.03).

Conclusions

Patients over 80 years of age have a relatively high incidence of DCIS and receive low relative rates of treatment. Although surgery does not provide a survival benefit for all patients over 80, it does provide a significant survival benefit for patients with high grade DCIS. Our results suggest that perhaps the biology of the DCIS, not the age of the patient should direct who warrants treatment.

Estevez LG, Alvarez I, Segui MA, Munoz M, Margeli M, Miro C, Rubio C, Lluch A, Tusquets I (2010) Current perspectives of treatment of ductal carcinoma in situ. Cancer Treat Rev 36(7):507–517CrossRefPubMed

Kerlikowske K (2010) Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010(41):139–141CrossRefPubMedPubMedCentral

Cheung S, Booth ME, Kearins O, Dodwell D (2014) Risk of subsequent invasive breast cancer after a diagnosis of ductal carcinoma in situ (DCIS). Breast 23(6):807–811CrossRefPubMed

Benson JR, Jatoi I, Toi M (2016) Treatment of low-risk ductal carcinoma in situ: is nothing better than something? Lancet Oncol 17(10):e442–e451CrossRefPubMed

Merrill AL, Esserman L, Morrow M (2016) Clinical decisions. Ductal carcinoma in situ. N Engl J Med 374(4):390–392CrossRefPubMed

Francis A, Thomas J, Fallowfield L, Wallis M, Bartlett JM, Brookes C, Roberts T, Pirrie S, Gaunt C, Young J et al (2015) Addressing overtreatment of screen detected DCIS: the LORIS trial. Eur J Cancer 51(16):2296–2303CrossRefPubMed

de Gelder R, Heijnsdijk EA, van Ravesteyn NT, Fracheboud J, Draisma G, de Koning HJ (2011) Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev 33:111–121CrossRefPubMedPubMedCentral

Silverstein MJ, Lagios MD (2015) Treatment selection for patients with ductal carcinoma in situ (DCIS) of the breast using the University of Southern California/Van Nuys (USC/VNPI) prognostic index. Breast J 21(2):127–132CrossRefPubMed

Patani N, Khaled Y, Al Reefy S, Mokbel K (2011) Ductal carcinoma in situ: an update for clinical practice. Surg Oncol 20(1):e23–e31CrossRefPubMed

10.

Sagara Y, Mallory MA, Wong S, Aydogan F, DeSantis S, Barry WT, Golshan M (2015) Survival benefit of breast surgery for low-grade ductal carcinoma in situ: a population-based cohort study. JAMA Surg 150(8):739–745CrossRefPubMed

11.

Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman LJ (2011) Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat 129(1):165–173CrossRefPubMed

12.

Kerlikowske K, Salzmann P, Phillips KA, Cauley JA, Cummings SR (1999) Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness. JAMA 282(22):2156–2163CrossRefPubMed

13.

Walter LC, Covinsky KE (2001) Cancer screening in elderly patients: a framework for individualized decision making. JAMA 285(21):2750–2756CrossRefPubMed

14.

Kerlikowske K, Grady D, Barclay J, Sickles EA, Eaton A, Ernster V (1993) Positive predictive value of screening mammography by age and family history of breast cancer. JAMA 270(20):2444–2450CrossRefPubMed

15.

Oeffinger KC, Fontham ET, Etzioni R, Herzig A, Michaelson JS, Shih YC, Walter LC, Church TR, Flowers CR, LaMonte SJ et al (2015) Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA 314(15):1599–1614CrossRefPubMedPubMedCentral

16.

Corbelli J, Borrero S, Bonnema R, McNamara M, Kraemer K, Rubio D, Karpov I, McNeil M (2014) Physician adherence to U.S. preventive services task force mammography guidelines. Womens Health Issues 24(3):e313–e319CrossRefPubMed

17.

Surveillance Epidemiology, and End Results (SEER) Program (http://www.seer.cancer.gov/) Research Data (1973–2013) National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission

18.

Nelson HD, Tyne K, Naik A, Bougatsos C, Chan B, Nygren P, Humphrey L (2009) Screening for breast cancer: systematic evidence review update for the US preventive services task force. Ann Intern Med 151:727–737CrossRefPubMedPubMedCentral

19.

Badgwell BD, Giordano SH, Duan ZZ, Fang S, Bedrosian I, Kuerer HM, Singletary SE, Hunt KK, Hortobagyi GN, Babiera G (2008) Mammography before diagnosis among women age 80 years and older with breast cancer. J Clin Oncol 26(15):2482–2488CrossRefPubMed

20.

Wang SY, Shamliyan T, Virnig BA, Kane R (2011) Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Breast Cancer Res Treat 127(1):1–14CrossRefPubMed

21.

Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, Housman MG, Escarce JJ (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21(7):1383–1389CrossRefPubMed

Title: Incidence and treatments of DCIS in octogenarians: grade matters
Authors: Erin P. Ward
Anna Weiss
Sarah L. Blair
Publication date: 01-09-2017
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4330-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2017

Breast cancer electron intraoperative radiotherapy: assessment of preoperative selection factors from a retrospective analysis of 758 patients and review of literature

Is there a role for sentinel node biopsy in the pre-operative ultrasound positive axilla?

COX2 induction: a mechanism of endocrine breast cancer resistance?

Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study

Response Letter

Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer